The case for & against
Bull & Bear analysis
Bearish
BiomX Inc. (NASDAQ: BIMO) is a biotechnology company specializing in innovative phage therapy solutions targeted at combating challenging bacterial infections, particularly in cystic fibrosis (CF) and diabetic foot osteomyelitis (DFO). The company is currently navigating the complex landscape of phage-based therapeutics, present in the rapidly evolving biopharmaceutical path to address substantial unmet medical needs. With recent advancements including strategic acquisitions and clinical trials, BiomX aims to establish itself as a leader in the antibiotic resistance domain while capturing significant market share in therapeutic solutions.
Bull says
- ↑BX211 trial achieved >40% reduction in ulcer size by week 10.
- ↑$15.2M cash balance as of June 2025 funds operations into Q1 2026.
- ↑FDA provided constructive guidance for BX011, aiding BLA pathway.
- ↑Targets 160K U.S. diabetic amputations annually; no DFO therapy approved in 20+ years.
- ↑$40M non-dilutive DHA funding endorses pipeline and limits dilution.
- ↑Strong liquidity and favorable book-to-price ratio suggest value opportunity.
Bear says
- ↓Q3 2025 net loss $9.2M and $22M cash used in ops signal financial strain.
- ↓Clinical hold on BX004 demands extra data, delaying pivotal trials.
- ↓Ongoing recruitment difficulties could push back critical data readouts.
- ↓Negative earnings yield, leverage, and volatility factors indicate instability.
- ↓Elevated short interest reflects market skepticism on phage adoption.
- ↓Rising competition in antibiotic resistance may compress future margins.
Earnings Call · Q2 2024 · Mgmt. Guidance
Updated 07-15-2026neutral
Transcript signals
Bull points
- We estimate that our cash, cash equivalents, and short-term deposits are sufficient to fund our operations through the fourth quarter of 2025.
- Net income was $4.5 million for the second quarter of 2024, compared to a net loss of $6.4 million for the same period in 2023.
- We estimate that our cash, cash equivalents, and short-term deposits are sufficient to fund our operations through the fourth quarter of 2025.
Bear points
- Net cash used in operating activities for the six months ended June 30, 2024, was $22.6 million, compared to $9.1 million for the same period in 2023.
- Net cash used in operating activities for the six months ended June 30, 2024, was $22.6 million, compared to $9.1 million for the same period in 2023.
- So, again, this is still a small study. We're not looking at stat sig. I think we'll be interested in trends. But if you see something like that, then I think that could be, you know, something that we'll be excited about.
Read full transcript analysis ›